Phase II and III drugs for the treatment of fragile X syndrome

Bibliography

• Turner G, Webb T, Wake S, Robinson H. Prevalence of fragile X syndrome. Am J Med Genet 1996;64:196-7
   PubMed Web of Science ®Google Scholar
• Pesso R, Berkenstadt M, Cuckle H, Screening for fragile X syndrome in women of reproductive age. Prenat Diagn 2000;20:611-14
   PubMedGoogle Scholar
• Hagerman PJ. The fragile X prevalence paradox. J Med Genet 2008;45:498-9
   PubMed Web of Science ®Google Scholar
• Verkerk AJMH, Pieretti M, Sutcliffe JS, Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991;65:905-14
   PubMed Web of Science ®Google Scholar
• Ashley CT Jr, Wilkinson KD, Reines D, Warren ST. FMR1 protein: conserved RNP family domains and selective RNA binding. Science 1993;262:563-6
   PubMed Web of Science ®Google Scholar
• Siomi H, Siomi MC, Nussbaum RL, Dreyfuss G. The protein product of the fragile X gene, FMR1, has characteristics of an RNA-binding protein. Cell 1993;74:291-8
   PubMed Web of Science ®Google Scholar
• Feng Y, Absher D, Eberhart DE, FMRP Associates with polyribosomes as an mRNP, and the I304N mutation of severe fragile X syndrome abolishes this association. Mol Cell 1997;1:109-18
   PubMed Web of Science ®Google Scholar
• Verheij C, Bakker CE, de Graaff E, Characterization and localization of the FMR-1 gene product associated with fragile X syndrome. Nature 1993;363:722-4
   PubMed Web of Science ®Google Scholar
• Li Z, Zhang Y, Ku L, The fragile X mental retardation protein inhibits translation via interacting with mRNA. Nucleic Acids Res 2001;29:2276
   PubMed Web of Science ®Google Scholar
• Darnell JC, Jensen KB, Jin P, Fragile X mental retardation protein targets G quartet mRNAs important for neuronal function. Cell 2001;107:489-99
   PubMed Web of Science ®Google Scholar
• Tassone F, Hagerman RJ, Taylor AK, Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. Am J Hum Gent 2000;66:6-15
   PubMed Web of Science ®Google Scholar
• Brunberg JA, Jacquemont S, Hagerman RJ, Fragile X premutation carriers: characteristic MR imaging findings of adult male patients with progressive cerebellar and cognitive dysfunction. AJNR Am J Neuroradiol 2002;23:1757-66
   PubMed Web of Science ®Google Scholar
• Greco CM, Hagerman RJ, Tassone F, Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers. Brain 2002;125:1760-71
   PubMed Web of Science ®Google Scholar
• Hagerman PJ, Hagerman RJ. Fragile X-associated Tremor/Ataxia Syndrome (FXTAS). Ment Retard Devel Disabil Res Rev 2004;10:25-30
   PubMedGoogle Scholar
• Tsiouris JA, Brown WT. Neuropsychiatric symptoms of fragile X syndrome: pathophysiology and pharmacotherapy. CNS Drugs 2004;18:687-703
   Google Scholar
• Hagerman RJ, Berry-Kravis E, Kaufmann WE, Advances in the treatment of fragile X syndrome. Pediatrics 2009;123:378-90
   PubMed Web of Science ®Google Scholar
• Hatton DD, Sideris J, Skinner M, Autistic behavior in children with fragile X syndrome: prevalence, stability, and the impact of FMRP. Am J Med Genet A 2006;140A:1804-13
   PubMed Web of Science ®Google Scholar
• Tranfaglia MR. The psychiatric presentation of fragile X: evolution of the diagnosis and treatment of the psychiatric comorbidities of fragile X syndrome. Dev Neurosci 2011;33:337-48
   PubMed Web of Science ®Google Scholar
• Cordeiro L, Ballinger E, Hagerman R, Hessl D. Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: prevalence and characterization. J Neurodev Disord 2011;3:57-67
   PubMed Web of Science ®Google Scholar
• Brown WT, Jenkins EC, Krawczun MS, The fragile X syndrome. Ann NY Acad Sci 1986;477:129-50
   Google Scholar
• Loesch DZ, Huggins RM, Bui QM, Effect of fragile X status categories and FMRP deficits on cognitive profiles estimated by robust pedigree analysis. Am J Med Genet A 2003;122A:13-23
   Google Scholar
• Loesch DZ, Huggins RM, Hagerman RJ. Phenotypic variation and FMRP levels in fragile X. Ment Retard Devel Disabil Res Rev 2004;10:31-41
   PubMedGoogle Scholar
• Hagerman RJ, Jackson C, Amiri K, Girls with fragile X syndrome: physical and neurocognitive status and outcome. Pediatrics 1992;89:395-400
   Google Scholar
• De Vries BB, Wiegers AM, Smits AP, Mental status of females with an FMR1 gene full mutation. Am J Hum Genet 1996;58:1025
   PubMed Web of Science ®Google Scholar
• Martinez R, Bonilla-Henao V, Jimenez A, Skewed X inactivation of the normal allele in fully mutated female carriers determines the levels of FMRP in blood and the fragile X phenotype. Mol Diagn 2005;9:157-62
   Google Scholar
• Tassone F, Hagerman RJ, Taylor AK, Clinical involvement and protein expression in individuals with the FMR1 premutation. Am J Med Genet 2000;91:144-52
   Google Scholar
• Allingham-Hawkins DJ, Babul-Hirji R, Chitayat D, Fragile X premutation is a significant risk factor for premature ovarian failure: the international collaborative POF in fragile X study—preliminary data. Am J Med Genet 1999;83:322-5
   PubMed Web of Science ®Google Scholar
• Spath MA, Nillesen WN, Smits APT, X chromosome inactivation does not define the development of premature ovarian failure in fragile X premutation carriers. Am J Med Genet A 2010;152A:387-93
   Google Scholar
• Hagerman RJ, Leehey M, Heinrichs W, Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 2001;57:127-30
   PubMed Web of Science ®Google Scholar
• Jacquemont S, Hagerman RJ, Leehey M, Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet 2003;72:869-78
   PubMed Web of Science ®Google Scholar
• Jacquemont S, Leehey MA, Hagerman RJ, Size bias of fragile X premutation alleles in late onset-onset movement disorders. J Med Genet 2006;43:804-9
   PubMed Web of Science ®Google Scholar
• Bailey DB, Raspa M, Bishop E, Medication utilization for targeted symptoms in children and adults with fragile X syndrome. J Dev Behav Pediatr 2012;33:62-9
   PubMed Web of Science ®Google Scholar
• Erickson CA, Stigler KA, Wink LK, A prospective open-label study of aripiprazole in fragile X syndrome. Psychopharmacology 2011;216:85-90
   PubMed Web of Science ®Google Scholar
• Lejeune J, Rethore MO, de Blois MC, Trial of folic acid treatment in fragile X syndrome. Ann Genet 1984;27:230-2
   Google Scholar
• Brown WT, Cohen IL, Fisch GS, High dose folic acid treatment of fragile (X) males. Am J Med Genet 1986;23:263-71
   Google Scholar
• Hagerman RJ, Jackson AW, Levitas A, Oral folic acid versus placebo in the treatment of males with the fragile X syndrome. Am J Med Genet 1986;23:241-62
   Google Scholar
• Wells TE, Madison LS. Assessment of behavior change in a fragile-X syndrome male treated with folic acid. Am J Med Genet 1986;23:291-6
   Google Scholar
• Gillberg C, Wahlstrom J, Johansson R, Folic acid as an adjunct in the treatment of children with the autism fragile-X syndrome (AFRAX). Dev Med Child Neurol 1986;28:624-7
   Google Scholar
• Froster-Iskenius U, Bodeker K, Oepen T, Folic acid treatment in males and females with fragile-(X)-syndrome. Am J Med Genet 1986;23:273-89
   Google Scholar
• Fisch GS, Cohen IL, Gross AC, Folic acid treatment of fragile X males: a further study. Am J Med Genet 1988;30:393-9
   Google Scholar
• Strom CM, Brusca RM, Pizzi WJ. Double-blind, placebo-controlled crossover study of folinic acid (Leucovorin®) for the treatment of fragile X syndrome. Am J Med Genet 1992;44:676-82
   Google Scholar
• Rueda J-R, Ballesteros J, Guillen V, Folic acid for fragile X syndrome. Cochrane Database Syst Rev John Wiley & Sons, Ltd, 2011(5):CD008476
   Google Scholar
• Hagerman RJ, Murphy MA, Wittenberger MD. A controlled trial of stimulant medication in children with the fragile X syndrome. Am J Med Genet 1988;30:377-92
   Web of Science ®Google Scholar
• Roberts J, Miranda M, Boccia M, Treatment effects of stimulant medication in young boys with fragile X syndrome. J Neurodevel Disord 2011;3:175-84
   PubMed Web of Science ®Google Scholar
• Pascale E, Battiloro E, Reale GC, Modulation of methylation in the FMR1 promoter region after long term treatment with L-carnitine and acetyl-L-carnitine. J Med Genet 2003;40:e76-6
   Google Scholar
• Torrioli MG, Vernacotola S, Mariotti P, Double-blind, placebo-controlled study of L-acetylcarnitine for the treatment of hyperactive behavior in fragile X syndrome. Am J Med Genet 1999;87:366-8
   Google Scholar
• Torrioli MG, Vernacotola S, Peruzzi L, A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys. Am J Med Genet A 2008;146:803-12
   Google Scholar
• Torrioli MG, Vernacotola S, Setini C, Treatment with valproic acid ameliorates ADHD symptoms in fragile X syndrome boys. Am J Med Genet A 2010;152:1420-7
   Google Scholar
• Wirojanan J, Jacquemont S, Diaz R, The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. J Clin Sleep Med 2009;5:145
   PubMed Web of Science ®Google Scholar
• Bakker CE, Verheij C, Willemsen R, Fmr1 knockout mice: a model to study fragile X mental retardation. Cell 1994;78:23-33
   PubMed Web of Science ®Google Scholar
• Comery TA, Harris JB, Willems PJ, Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits. Proc Natl Acad Sci 1997;94:5401-4
   PubMedGoogle Scholar
• Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci 2004;27:370-7
   PubMed Web of Science ®Google Scholar
• Kooy RF. Of mice and the fragile X syndrome. Trends Genet 2003;19:148-54
   PubMed Web of Science ®Google Scholar
• Nimchinsky EA, Oberlander AM, Svoboda K. Abnormal development of dendritic spines in FMR1 knock-out mice. J Neurosci 2001;21:5139-46
   PubMed Web of Science ®Google Scholar
• Vanderklish PW, Edelman GM. Dendritic spines elongate after stimulation of group 1 metabotropic glutamate receptors in cultured hippocampal neurons. Proc Natl Acad Sci 2002;99:1639-44
   PubMed Web of Science ®Google Scholar
• Zhang YQ, Bailey AM, Matthies HJG, Drosophila fragile X-related gene regulates the MAP1B homolog Futsch to control synaptic structure and function. Cell 2001;107:591-603
   PubMed Web of Science ®Google Scholar
• Berry-Kravis E, Knox A, Hervey C. Targeted treatments for fragile X syndrome. J Neurodevel Disord 2011;3:193-210
   PubMed Web of Science ®Google Scholar
• Brown V, Jin P, Ceman S, Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell 2001;107:477-87
   PubMed Web of Science ®Google Scholar
• Wang H, Dictenberg JB, Ku L, Dynamic association of the fragile X mental retardation protein as a messenger ribonucleoprotein between microtubules and polyribosomes. Mol Biol Cell 2008;19:105-14
   PubMed Web of Science ®Google Scholar
• Weiler IJ, Irwin SA, Klintsova AY, Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation. Proc Natl Acad Sci 1997;94:5395
   PubMed Web of Science ®Google Scholar
• Westmark CJ, Westmark PR, Malter JS. MPEP reduces seizure severity in Fmr-1 KO mice over expressing human Abeta. Int J Clin Exp Pathol 2010;3:56-68
   Google Scholar
• Huber KM. Role for rapid dendritic protein synthesis in hippocampal mGluR-dependent long-term depression. Science 2000;288:1254-6
   PubMed Web of Science ®Google Scholar
• Snyder EM, Philpot BD, Huber KM, Internalization of ionotropic glutamate receptors in response to mGluR activation. Nat Neurosci 2001;4:1079-85
   PubMed Web of Science ®Google Scholar
• Qin M, Kang J, Burlin TV, Postadolescent changes in regional cerebral protein synthesis: an in vivo study in the Fmr1 null mouse. J Neurosci 2005;25:5087-95
   PubMed Web of Science ®Google Scholar
• Dolen G, Carpenter RL, Ocain TD, Bear MF. Mechanism-based approaches to treating fragile X. Pharmacol Ther 2010;127:78-93
   PubMed Web of Science ®Google Scholar
• Bittel DC, Kibiryeva N, Butler MG. Whole genome microarray analysis of gene expression in subjects with fragile X syndrome. Genet Med 2007;9:464-72
   Web of Science ®Google Scholar
• Lu R, Wang H, Liang Z, The fragile X protein controls microtubule-associated protein 1B translation and microtubule stability in brain neuron development. Proc Natl Acad Sci 2004;101:15201
   PubMed Web of Science ®Google Scholar
• Brown MR, Kronengold J, Gazula V-R, Fragile X mental retardation protein controls gating of the sodium-activated potassium channel Slack. Nat Neurosci 2010;13:819-21
   PubMed Web of Science ®Google Scholar
• Suvrathan A, Hoeffer CA, Wong H, Characterization and reversal of synaptic defects in the amygdala in a mouse model of fragile X syndrome. Proc Natl Acad Sci 2010;107:11591-6
   Google Scholar
• Huber KM, Gallagher SM, Warren ST, Bear MF. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci 2002;99:7746-50
   PubMed Web of Science ®Google Scholar
• Nakamoto M, Nalavadi V, Epstein MP, Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors. Proc Natl Acad Sci 2007;104:15537
   PubMedGoogle Scholar
• D'Hulst C, De Geest N, Reeve SP, Decreased expression of the GABAA receptor in fragile X syndrome. Brain Res 2006;1121:238-45
   PubMed Web of Science ®Google Scholar
• Heulens I, D'Hulst C, Van Dam D, Pharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse model. Behav Brain Res 2012;229(1):244-9
   Google Scholar
• Bear MF. Therapeutic implications of the mGluR theory of fragile X mental retardation. Genes Brain Behav 2005;4:393-8
   PubMedGoogle Scholar
• McBride SMJ, Choi CH, Wang Y, Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron 2005;45:753-64
   PubMed Web of Science ®Google Scholar
• Dolen G, Bear MF. Courting a Cure for Fragile X. Neuron 2005;45:642-4
   PubMedGoogle Scholar
• Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP. Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 2005;49:1053-66
   PubMed Web of Science ®Google Scholar
• Dolen G, Osterweil E, Rao BSS, Correction of fragile X syndrome in mice. Neuron 2007;56:955-62
   PubMed Web of Science ®Google Scholar
• Bear MF, Dolen G, Osterweil E, Nagarajan N. Fragile X: translation in action. Neuropsychopharmacology 2008;33:84-7
   PubMed Web of Science ®Google Scholar
• Thomas A, Bui N, Perkins J, Yuva-Paylor L. Group I metabotropic glutamate receptor antagonists alter select behaviors in a mouse model for fragile X syndrome. Psychopharmacology (Berl) 2012;219:47-58
   PubMed Web of Science ®Google Scholar
• de Vrij FMS, Levenga J, van der Linde HC, Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol Dis 2008;31:127-32
   PubMed Web of Science ®Google Scholar
• Levenga J, Hayashi S, de Vrij F, AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome. Neurobiol Dis 2011;42:311-17
   PubMed Web of Science ®Google Scholar
• Porter RHP. Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J Pharmacol Exp Ther 2005;229(1):244-9
   Google Scholar
• Pecknold JC, McClure DJ, Appeltauer L, Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study. J Clin Psychopharmacol 1982;2:129-32
   PubMed Web of Science ®Google Scholar
• Berry-Kravis E, Hessl D, Coffey S, A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet 2009;46:266-71
   PubMed Web of Science ®Google Scholar
• Vinueza Veloz MF, Buijsen RAM, Willemsen R, The effect of an mGluR5 inhibitor on procedural memory and avoidance discrimination impairments in Fmr1 KO mice. Genes Brain Behav 2012;11:325-31
   Google Scholar
• Jacquemont S, Curie A, des Portes V, Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential responses to the mGluR5 antagonist AFQ056. Sci Transl Med 2011;3:64ra1
   PubMed Web of Science ®Google Scholar
• Tabolacci E, Pirozzi F, Gomez-Mancilla B, The mGluR5 antagonist AFQ056 does not affect methylation and transcription of the mutant FMR1 gene in vitro. BMC Med Genet 2012;13:13-17
   Google Scholar
• Novartis. Safety and efficacy of AFQ056 in adult patients with fragile X syndrome. NIH: clinicalTrials.gov. 2012. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01253629?term=AFQ056+and+fragile+x&rank=4 [Last accessed 30 September 2012]
   Google Scholar
• Novartis. Safety and efficacy of AFQ056 in adolescent patients with fragile X syndrome. NIH: clinicalTrials.gov. 2012. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01357239?term=AFQ056+and+fragile+x&rank=1 [Last accessed 30 September 2012]
   Google Scholar
• Novartis. Long-term, safety, tolerability and efficacy study of AFQ056 in adult patients with fragile X syndrome. NIH: clinicalTrials.gov. 2012. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01348087?term=AFQ056+and+fragile+x&rank=2 [Last accessed 30 September 2012]
   Google Scholar
• Novartis. Long-term, safety and tolerability study of AFQ056 in adolescent patients with fragile X syndrome (open-label). NIH: clinicalTrials.gov. 2012. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01433354?term=AFQ056+and+fragile+x&rank=3 [Last accessed 30 September 2012]
   Google Scholar
• Novartis. Clinical study to assess the pharmacokinetics, safety and tolerability of single and multiple oral doses of AFQ056 in children with fragile X syndrome (FXS). NIH: clinicalTrials.gov. 2012. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01482143?term=AFQ056+and+fragile+x&rank=5 [Last accessed 30 September 2012]
   Google Scholar
• Erickson CA, Mullett JE, McDougle Christopher J. Brief Report: acamprosate in fragile X syndrome. J Autism Devel Disord 2010;40:1412-16
   Google Scholar
• Indiana University. Acamprosate in youth with fragile X syndrome. NIH: clinicalTrials.gov. 2011. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01300923?term=acamprosate+fragile+x&rank=1 [Last accessed 30 September 2012]
   Google Scholar
• NIH. Search of: RO4917523 - list results - ClinicalTrials.gov. NIH: clinicalTrials.gov. 2012. Available from: http://www.clinicaltrials.gov/ct2/results?term=RO4917523&Search=Search [Last accessed 30 September 2012]
   Google Scholar
• NIH. Search of: STX107- list results- ClinicalTrials.gov. NIH: clinicalTrials.gov. 2012. Available from: http://www.clinicaltrials.gov/ct2/results?term=stx107&Search=Search [Last accessed 30 September 2012]
   Google Scholar
• Lindemann L, Jaeschke G, Michalon A, CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor. J Pharmacol Exp Ther 2011;339:474-86
   PubMed Web of Science ®Google Scholar
• Michalon A, Sidorov M, Ballard TM, Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron 2012;74:49-56
   PubMed Web of Science ®Google Scholar
• Erickson CA, Weng N, Weiler IJ, Open-label riluzole in fragile X syndrome. Brain Res 2011;1380:264-70
   PubMed Web of Science ®Google Scholar
• Erickson CA, Mullett JE, McDougle Christopher J. Open-label memantine in fragile X syndrome. J Autism Devel Disord 2009;39:1629-35
   Google Scholar
• Wei H, Dobkin C, Sheikh AM, The therapeutic effect of memantine through the stimulation of synapse formation and dendritic spine maturation in autism and fragile X syndrome. PLoS One 2012;7:e36981
   Google Scholar
• Ortigas MC, Bourgeois JA, Schneider A, Improving Fragile X-Associated Tremor/Ataxia Syndrome symptoms with memantine and venlafaxine. J Clin Psychopharmacol 2010;30:642-4
   Google Scholar
• Bilousova TV, Dansie L, Ngo M, Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet 2008;46:94-102
   Google Scholar
• Siller SS, Broadie K. Matrix Metalloproteinases and minocycline: therapeutic avenues for fragile X syndrome. Neural Plast 2012;2012:1-9
   Google Scholar
• Paribello C, Tao L, Folino A, Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol 2010;10:91
   PubMed Web of Science ®Google Scholar
• Siller SS, Broadie K. Neural circuit architecture defects in a Drosophila model of Fragile X syndrome are alleviated by minocycline treatment and genetic removal of matrix metalloproteinase. Dis Model Mech 2011;4:673-85
   Google Scholar
• Rotschafer SE, Trujillo MS, Dansie LE, Minocycline treatment reverses ultrasonic vocalization production deficit in a mouse model of Fragile X Syndrome. Brain Res 2012;1439:7-14
   Google Scholar
• University of California, Davis. Trial of minocycline to treat children with fragile X syndrome. NIH: clinicalTrials.gov. 2012. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01053156?term=fragile+x+syndrome+and+minocycline&rank=1 [Last accessed 30 September 2012]
   Google Scholar
• Utari A, Chonchaiya W, Rivera SM, Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures. Am J Intellect Dev Disabil 2010;115:433-43
   Google Scholar
• Berry-Kravis E, Sumis A, Hervey C, Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Devel Behav Pediatr 2008;29:293
   PubMed Web of Science ®Google Scholar
• Min WW, Yuskaitis CJ, Yan Q, Elevated glycogen synthase kinase-3 activity in Fragile X mice: key metabolic regulator with evidence for treatment potential. Neuropharmacology 2009;56:463-72
   PubMed Web of Science ®Google Scholar
• Liu Z-H, Chuang D-M, Smith CB. Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome. Int J Neuropsychopharmacol 2012;14:618-30
   Google Scholar
• Yuskaitis CJ, Mines MA, King MK, Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of Fragile X syndrome. Biochem Pharmacol 2010;79:632-46
   Google Scholar
• Mines MA, Yuskaitis CJ, King MK, GSK3 Influences Social Preference and Anxiety-Related Behaviors during Social Interaction in a Mouse Model of Fragile X Syndrome and Autism. PLoS ONE 2010;5:e9706
   PubMed Web of Science ®Google Scholar
• Choi CH, Schoenfeld BP, Bell AJ, Pharmacological reversal of synaptic plasticity deficits in the mouse model of fragile X syndrome by group II mGluR antagonist or lithium treatment. Brain Res 2011;1380:106-19
   PubMed Web of Science ®Google Scholar
• Liu Z-H, Huang T, Smith CB. Lithium reverses increased rates of cerebral protein synthesis in a mouse model of fragile X syndrome. Neurobiol Dis 2012;45:1145-52
   Google Scholar
• Hopkins CR. ACS chemical neuroscience molecule spotlight on STX209 (arbaclofen). ACS Chem Neurosci 2011;2:381-1
   Google Scholar
• Pacey LKK, Heximer SP, Hampson DR. Increased GABAB receptor-mediated signaling reduces the susceptibility of fragile X knockout mice to audiogenic seizures. Mol Pharmacol 2009;76:18-24
   PubMed Web of Science ®Google Scholar
• Pacey LKK, Tharmalingam S, Hampson DR. Subchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndrome. J Pharmacol Exp Ther 2011;338:897-905
   Google Scholar
• Henderson C, Wijetunge L, Kinoshita MN, Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci Transl Med 2012;4:152ra128
   PubMed Web of Science ®Google Scholar
• Berry-Kravis EM, Hessl D, Rathmell B, Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med 2012;4:152ra127
   PubMed Web of Science ®Google Scholar
• Seaside Therapeutics. News: seaside Therapeutics reports positive data from phase 2 study of STX209 in autism spectrum disorders. Seaside Therapeutics. 2010. Available from: http://www.seasidetherapeutics.com/news [Last accessed 30 September 2012]
   Google Scholar
• Seaside Therapeutics. A fixed-dose study of the efficacy, safety, and tolerability of STX209 (arbaclofen) administered for the treatment of social withdrawal in children with fragile X syndrome. NIH: clinicalTrials.gov. 2012. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01325220?term=STX209&rank=3 [Last accessed 30 September 2012]
   Google Scholar
• Arai A, Kessler M, Xiao P, A centrally active drug that modulates AMPA receptor gated currents. Brain Res 1994;638:343-6
   PubMed Web of Science ®Google Scholar
• Arai A, Kessler M, Rogers G, Effects of a memory-enhancing drug on DL-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor currents and synaptic transmission in hippocampus. J Pharmacol Exp Ther 1996;278:627-38
   PubMed Web of Science ®Google Scholar
• Lynch G. AMPA receptor modulators as cognitive enhancers. Curr Opin Pharmacol 2004;4:4-11
   PubMed Web of Science ®Google Scholar
• Staubli U, Rogers G, Lynch G. Facilitation of glutamate receptors enhances memory. Proc Natl Acad Sci 1994;91:777-81
   PubMed Web of Science ®Google Scholar
• Hampson RE, Rogers G, Lynch G, Facilitative effects of the ampakine CX516 on short-term memory in rats: enhancement of delayed-nonmatch-to-sample performance. J Neurosci 1998;18:2740-7
   PubMed Web of Science ®Google Scholar
• Hampson RE, Rogers G, Lynch G, Deadwyler SA. Facilitative effects of the ampakine CX516 on short-term memory in rats: correlations with hippocampal neuronal activity. J Neurosci 1998;18:2748-63
   PubMed Web of Science ®Google Scholar
• Lynch G, Granger R, Ambros-Ingerson J, Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans. Exp Neurol 1997;145:89-92
   PubMed Web of Science ®Google Scholar
• Goff DC, Leahy L, Berman I, A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol 2001;21:484-7
   PubMed Web of Science ®Google Scholar
• Berry-Kravis E, Krause SE, Block SS, Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. J Child Adolesc Psychopharmacol 2006;16:525-40
   PubMed Web of Science ®Google Scholar
• Hollander E, Bartz J, Chaplin W, Oxytocin increases retention of social cognition in autism. Biol Psychiatry 2007;61:498-503
   PubMed Web of Science ®Google Scholar
• Andari E, Duhamel J-R, Zalla T, Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. Proc Natl Acad Sci 2010;107:4389-94
   PubMed Web of Science ®Google Scholar
• Guastella AJ, Einfeld SL, Gray KM, Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry 2010;67:692-4
   PubMed Web of Science ®Google Scholar
• Hollander E, Novotny S, Hanratty M, Oxytocin infusion reduces repetitive behaviors in adults with Autistic and Asperger's Disorders. Neuropsychopharmacology 2003;28:193-8
   PubMed Web of Science ®Google Scholar
• Hall SS, Lightbody AA, McCarthy BE, Effects of intranasal oxytocin on social anxiety in males with fragile X syndrome. Psychoneuroendocrinology 2012;37:509-18
   PubMed Web of Science ®Google Scholar
• Kesler SR, Lightbody AA, Reiss AL. Cholinergic dysfunction in fragile X syndrome and potential intervention: a preliminary 1H MRS study. Am J Med Genet A 2009;149:403-7
   Web of Science ®Google Scholar
• Stanford University. Randomized controlled study of donepezil in fragile X syndrome. NIH: clinicalTrials.gov. 2012. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01120626?term=fragile+x+and+donepezil&rank=2 [Last accessed 30 September 2012]
   Google Scholar
• Sansone S, Widaman K, Hall S, Psychometric study of the Aberrant Behavior Checklist in fragile X syndrome and implications for targeted treatment. J Autism Dev Disord 2012;42:1377-92
   PubMed Web of Science ®Google Scholar
• Won H, Lee H-R, Gee HY, Autistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function. Nature 2012;486:261-5
   PubMed Web of Science ®Google Scholar
• Moskal JR, Burgdorf J, Kroes RA, A novel NMDA receptor glycine-site partial agonist, GLYX-13, has therapeutic potential for the treatment of autism. Neurosci Biobehav Rev 2011;35:1982-8
   PubMed Web of Science ®Google Scholar
• Posey DJ, Kem DL, Swiezy NB, A pilot study of D-cycloserine in subjects with autistic disorder. Am J Psychiatry 2004;161:2115-17
   PubMed Web of Science ®Google Scholar
• Goff DC, Herz L, Posever T, A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl) 2005;179:144-50
   PubMed Web of Science ®Google Scholar
• Nathan Kline Institute for Psychiatric Research. D-serine for the schizophrenia prodrome. NIH: clinicalTrials.gov. 2012. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00826202?term=D-serine+schizophrenia&rank=3 [Last accessed 30 September 2012]
   Google Scholar
• Zhang X, Sullivan JA, Moskal JR, Stanton PK. A NMDA receptor glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral-CA1 synapses in hippocampus. Neuropharmacology 2008;55:1238-50
   PubMed Web of Science ®Google Scholar
• Naurex, Inc. Phase 2, double-blind, placebo controlled, randomized withdrawal, parallel efficacy and safety study of GLYX-13 in subjects with inadequate/partial response to antidepressants during the current episode of Major Depressive Disorder. NIH: ClinicalTrials.gov. 2012. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01684163?term=GLYX-13&rank=1 [Last accessed: 30 September 2012]
   Google Scholar
• Kinon BJ, Gomez J-C. Clinical development of pomaglumetad methionil: a non-dopaminergic treatment for schizophrenia [Internet]. Neuropharmacology 2012; http://dx.doi.org.ezp-prod1.hul.harvard.edu/10.1016/neuropharm.2012.06.002
   Google Scholar
• Kinon BJ, Zhang L, Millen BA, A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol 2011;31:349-55
   PubMed Web of Science ®Google Scholar